Sensitivity of imatinib mesylate–resistant BCR-ABL–transformed cells to geldanamycin and 17-AAG
| Cell line . | Mean IC50 ± SD (μM) . | |
|---|---|---|
| GA . | 17-AAG . | |
| Ba/F3 + IL-3 | 27.3 ± 14.1 | 12.4 ± 0.3 |
| Ba/F3 P210 WT | 4.9 ± 1.6 | 5.2 ± 2.4 |
| Ba/F3 P210 T315I | 1.8 ± 2.1 (P = .03) | 2.3 ± 0.4 (P = .04) |
| Ba/F3 P210 E255K | 2.6 ± 2.4 (P = .05) | 1.0 ± 0.2 (P = .01) |
| Cell line . | Mean IC50 ± SD (μM) . | |
|---|---|---|
| GA . | 17-AAG . | |
| Ba/F3 + IL-3 | 27.3 ± 14.1 | 12.4 ± 0.3 |
| Ba/F3 P210 WT | 4.9 ± 1.6 | 5.2 ± 2.4 |
| Ba/F3 P210 T315I | 1.8 ± 2.1 (P = .03) | 2.3 ± 0.4 (P = .04) |
| Ba/F3 P210 E255K | 2.6 ± 2.4 (P = .05) | 1.0 ± 0.2 (P = .01) |
Representative data from at least 2 independent experiments performed in duplicate.
Differences in the mean IC50 values between wild-type (WT) and mutant P210 Ba/F3 cells were analyzed with the unpaired Studentt test; 2-tailed P values are shown.
IC50 indicates the concentration of inhibitor required to reduce the number of viable cells by 50%; GA, geldanamycin; 17-AAG, 17-allylaminogeldanamycin.